TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25565495

Group type: EXPERIMENTAL
Intervention: Social network intervention
Number of subjects: 626

Group type: COMPARATOR
Intervention: Standard HIV/STD testing/counseling
Number of subjects: 626
Study: 22451021

Group type: EXPERIMENTAL
Intervention: Non-thermal, non-invasive pulsed electromagnetic field (PEMF) therapy
Number of subjects: 34

Group type: COMPARATOR
Intervention: Sham cohort (placebo)
Number of subjects: 34
Study: 20142306

Group type: EXPERIMENTAL
Intervention: 10 μg dDAVP bolus (over 1 min)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 30 μg dDAVP incremental infusion (over 60 min)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 19261236

Group type: EXPERIMENTAL
Intervention: Alcohol (40 mg/100 ml)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Alcohol (moderate dose)
Number of subjects: 68
Study: 16428536

Group type: EXPERIMENTAL
Intervention: Methylprednisolone 125 mg IV
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Parecoxib 40 mg IV
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Methylprednisolone 125 mg IV and Parecoxib 40 mg IV
Number of subjects: 204
Study: 15571548

Group type: EXPERIMENTAL
Intervention: Sound cue
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Visual cue
Number of subjects: 49

Group type: COMPARATOR
Intervention: Low-risk elderly and younger subjects
Number of subjects: 49
Study: 11433626

Group type: EXPERIMENTAL
Intervention: Phone interview method
Number of subjects: 0

Group type: COMPARATOR
Intervention: Mail-out/mail-back method
Number of subjects: 0
Study: 10101927

Group type: EXPERIMENTAL
Intervention: High serum cortisol concentration
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low 17-ketosteroid level
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Obesity
Number of subjects: 0
Study: 8159194

Group type: EXPERIMENTAL
Intervention: Imipramine at a dose of 50 mg nightly
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Clonidine at a dose of 0.1 mg twice daily
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo twice daily
Number of subjects: 60
Study: 3355198

Group type: EXPERIMENTAL
Intervention: Anthralin in 0.0125% clobetasol propionate
Number of subjects: 35

Group type: COMPARATOR
Intervention: Anthralin in Lassar's paste
Number of subjects: 35
Study: 29730727

Group type: EXPERIMENTAL
Intervention: Healthy Habits, Healthy Girls-Brazil (H3G-Brazil) intervention emphasizing 10 key nutrition and physical activity messages over 6 months.
Number of subjects: 253

Group type: COMPARATOR
Intervention: Control group (no intervention prior to follow-up assessment).
Number of subjects: 253
Study: 29584681

Group type: EXPERIMENTAL
Intervention: Community resilience coalitions
Number of subjects: 16

Group type: COMPARATOR
Intervention: Preparedness coalitions
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Both coalition types
Number of subjects: 16
Study: 26698158

Group type: EXPERIMENTAL
Intervention: Achieve Mapping Catheter
Number of subjects: 102

Group type: COMPARATOR
Intervention: Lasso-guided procedure
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Second-generation cryoballoon
Number of subjects: 102
Study: 24382095

Group type: EXPERIMENTAL
Intervention: Early-onset alcohol and drug users (n=122; 67%)
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: Late-onset alcohol and drug users (n=60; 33%)
Number of subjects: 182
Study: 21830022

Group type: EXPERIMENTAL
Intervention: Neurofacilitation of Developmental Reaction (NFDR) approach
Number of subjects: 30

Group type: COMPARATOR
Intervention: Neurodevelopmental Therapy (NDT)
Number of subjects: 30
Study: 20051840

Group type: EXPERIMENTAL
Intervention: Enalapril (20 mg/day)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 17015043

Group type: EXPERIMENTAL
Intervention: Smoking cessation coupled with the use of an inhaled bronchodilator
Number of subjects: 5887

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 5887
Study: 15364322

Group type: EXPERIMENTAL
Intervention: SigmaSTR
Number of subjects: 700

Group type: EXPERIMENTAL
Intervention: MaxSTR
Number of subjects: 700

Group type: EXPERIMENTAL
Intervention: MaxSTPost
Number of subjects: 700

Group type: EXPERIMENTAL
Intervention: High Risk categorization
Number of subjects: 700
Study: 10840264

Group type: EXPERIMENTAL
Intervention: Intervention group (notified of GDS scores, offered educational sessions)
Number of subjects: 2346

Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 2346

Group type: COMPARATOR
Intervention: Control group (not notified of GDS scores, usual care)
Number of subjects: 2346

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 2346
Study: 9207721

Group type: EXPERIMENTAL
Intervention: Oral immunotherapy with encapsulated short ragweed extract
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 8401640

Group type: EXPERIMENTAL
Intervention: Electrified catheter (EC)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Nelaton catheter
Number of subjects: 24
Study: 3532799

Group type: EXPERIMENTAL
Intervention: Gestrinone 5 mg capsules twice weekly (Group A)
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Gestrinone 2.5 mg capsules three times weekly (Group B)
Number of subjects: 97

Group type: COMPARATOR
Intervention: Gestrinone 2.5 mg vaginal tablets three times weekly (Group C)
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Gestrinone treatment overall
Number of subjects: 97
Study: 3355003

Group type: EXPERIMENTAL
Intervention: TA surfactant
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31758329

Group type: EXPERIMENTAL
Intervention: Continuous regional arterial infusion (CRAI) of nafamostat mesilate (NM)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Intravenous administration (IV) of nafamostat mesilate (NM)
Number of subjects: 39
Study: 31294868

Group type: EXPERIMENTAL
Intervention: Rejuvenation of leukoreduced RBC units using Rejuvesol (pyruvate, inosine, phosphate, and adenine), warmed at 37°C for 60 minutes, followed by manual washing with saline adenine glucose mannitol solution.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rejuvenated RBCs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rejuvenation process
Number of subjects: 0
Study: 27939544

Group type: EXPERIMENTAL
Intervention: 100% orchardgrass (ORD)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: 50% orchardgrass + 50% Japanese millet (MIL)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: 50% orchardgrass + 50% brown midrib sorghum × sudangrass (SSG)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: 50% orchardgrass + 25% millet + 25% sorghum × sudangrass (MIX)
Number of subjects: 4
Study: 26456487

Group type: EXPERIMENTAL
Intervention: Intravitreal ranibizumab (IVT) - 3 monthly injections followed by PRN treatment
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Hemodilution (HD)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Combined treatment (IVT+HD)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Intravitreal ranibizumab (IVT)
Number of subjects: 44
Study: 23467506

Group type: EXPERIMENTAL
Intervention: BRU-training (Balance Rehabilitation Unit)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (usual falls prevention care)
Number of subjects: 60
Study: 20836754

Group type: EXPERIMENTAL
Intervention: Exercise training program
Number of subjects: 36

Group type: COMPARATOR
Intervention: Percutaneous coronary intervention (PCI)
Number of subjects: 36
Study: 18466801

Group type: EXPERIMENTAL
Intervention: Valsartan
Number of subjects: 3730

Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 3730

Group type: EXPERIMENTAL
Intervention: Combination of Valsartan and Captopril
Number of subjects: 3730

Group type: COMPARATOR
Intervention: Control (no specific intervention mentioned)
Number of subjects: 3730
Study: 16534882

Group type: EXPERIMENTAL
Intervention: Triple therapy (interferon (IFN‐alpha‐2b) 10 million units daily for 4 weeks followed by every other day for 20 weeks + ribavirin (600 or 800 mg/d) + polaprezinc (150 mg/d) for 24 weeks)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Dual therapy (interferon (IFN‐alpha‐2b) 10 million units daily for 4 weeks followed by every other day for 20 weeks + ribavirin (600 or 800 mg/d) for 24 weeks)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Triple therapy
Number of subjects: 102

Group type: COMPARATOR
Intervention: Dual therapy
Number of subjects: 102
Study: 14735184

Group type: EXPERIMENTAL
Intervention: Debulking surgery followed by i.p. chemotherapy (5-FU 550 mg m(‐2) day(‐1) i.p. and LV 60 mg m(‐2) day(‐1) i.v.)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control group treated with i.v. 5-FU+LV or i.v. methotrexate+5-FU+LV
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Patients who underwent macroscopically radical surgery
Number of subjects: 18
Study: 11518914

Group type: EXPERIMENTAL
Intervention: Metronidazole treatment
Number of subjects: 89
Study: 9434694

Group type: EXPERIMENTAL
Intervention: alpha-stat strategy
Number of subjects: 182

Group type: COMPARATOR
Intervention: pH-stat strategy
Number of subjects: 182
Study: 8518220

Group type: EXPERIMENTAL
Intervention: iproplatin
Number of subjects: 62

Group type: COMPARATOR
Intervention: carboplatin
Number of subjects: 62
Study: 3106101

Group type: EXPERIMENTAL
Intervention: Follicle-stimulating hormone (FSH)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Buserelin (0.3 ml twice a day subcutaneously for 14 days) followed by FSH
Number of subjects: 20
Study: 29718333

Group type: EXPERIMENTAL
Intervention: Electroconvulsive therapy (ECT)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Sham electroconvulsive therapy
Number of subjects: 29
Study: 28318865

Group type: EXPERIMENTAL
Intervention: Anterior PMDI
Number of subjects: 46

Group type: COMPARATOR
Intervention: Posterior PMDI
Number of subjects: 46
Study: 25646872

Group type: EXPERIMENTAL
Intervention: Trauma-Informed Medical Care (TI-Med) training
Number of subjects: 30

Group type: COMPARATOR
Intervention: Wait-list (delay) condition
Number of subjects: 30
Study: 23462342

Group type: EXPERIMENTAL
Intervention: Yoga classes and daily home practice
Number of subjects: 355

Group type: EXPERIMENTAL
Intervention: Supervised, facility-based aerobic exercise training
Number of subjects: 355

Group type: COMPARATOR
Intervention: Usual activity
Number of subjects: 355

Group type: EXPERIMENTAL
Intervention: Omega-3 supplement
Number of subjects: 355

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 355
Study: 20653371

Group type: EXPERIMENTAL
Intervention: Presentation with an explicit outline
Number of subjects: 27

Group type: COMPARATOR
Intervention: Presentation without an explicit outline
Number of subjects: 27
Study: 18271952

Group type: EXPERIMENTAL
Intervention: FASTHUG intervention implemented in 2005
Number of subjects: 0

Group type: COMPARATOR
Intervention: Historical control (2003)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Procedural interventions in 2004
Number of subjects: 0

Group type: COMPARATOR
Intervention: Comparison of pre-FASTHUG period (2003-2004)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Comparison of median pneumonia rate after FASTHUG
Number of subjects: 0
Study: 16984065

Group type: EXPERIMENTAL
Intervention: Empirical antisecretory therapy
Number of subjects: 722

Group type: EXPERIMENTAL
Intervention: Testing for Helicobacter pylori
Number of subjects: 722

Group type: EXPERIMENTAL
Intervention: Empirical antisecretory therapy followed by Helicobacter pylori testing if symptoms improved
Number of subjects: 722

Group type: COMPARATOR
Intervention: Combination strategy to empirical antisecretory treatment
Number of subjects: 722

Group type: COMPARATOR
Intervention: Combination strategy to H. pylori test alone
Number of subjects: 722
Study: 14594788

Group type: EXPERIMENTAL
Intervention: Blood ascorbate concentrations
Number of subjects: 1214

Group type: EXPERIMENTAL
Intervention: Alpha-tocopherol, beta-carotene, or retinol
Number of subjects: 1214

Group type: EXPERIMENTAL
Intervention: Dietary antioxidants measured by food-frequency questionnaire
Number of subjects: 1214
Study: 11187916

Group type: EXPERIMENTAL
Intervention: Intensive, multi-agent remission induction, early intensification with weekly, high-dose asparaginase, cranial radiation, frequent vincristine/corticosteroid pulses, doxorubicin for high-risk patients.
Number of subjects: 1255

Group type: COMPARATOR
Intervention: High-dose methotrexate during induction (protocol 87-01).
Number of subjects: 1255

Group type: COMPARATOR
Intervention: High-dose 6-mercaptopurine during intensification (protocol 91-01).
Number of subjects: 1255
Study: 9361611

Group type: EXPERIMENTAL
Intervention: J colonic pouch-anal anastomosis
Number of subjects: 40

Group type: COMPARATOR
Intervention: Straight coloanal anastomosis
Number of subjects: 40
Study: 1286496

Group type: EXPERIMENTAL
Intervention: Flumazenil (0.7 mg, 7 ml)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Placebo (9 ml)
Number of subjects: 240
Study: 2951796

Group type: EXPERIMENTAL
Intervention: Duovent (fenoterol and ipratropium bromide)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 31335741

Group type: EXPERIMENTAL
Intervention: Hou Gu Mi Xi (HGMX)
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: HGMX + rabeprazole
Number of subjects: 360

Group type: COMPARATOR
Intervention: Placebo + rabeprazole
Number of subjects: 360

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: HGMX
Number of subjects: 360
Study: 29727480

Group type: EXPERIMENTAL
Intervention: Emotional disclosure condition
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Cancer experience facts condition
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Self-regulation condition
Number of subjects: 96
Study: 26922022

Group type: EXPERIMENTAL
Intervention: Salbutamol (400 µg)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Ipratropium (80 µg)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Combined treatment (salbutamol and ipratropium)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Placebo (400 µg)
Number of subjects: 47
Study: 24304596

Group type: EXPERIMENTAL
Intervention: Total physical activity (PA)
Number of subjects: 785

Group type: EXPERIMENTAL
Intervention: Moderate-to-vigorous physical activity (MVPA)
Number of subjects: 785

Group type: EXPERIMENTAL
Intervention: Sleep duration
Number of subjects: 785

Group type: EXPERIMENTAL
Intervention: Sedentary time
Number of subjects: 785

Group type: EXPERIMENTAL
Intervention: Sleep disturbances
Number of subjects: 785

Group type: EXPERIMENTAL
Intervention: Changes in MVPA over time
Number of subjects: 785

Group type: EXPERIMENTAL
Intervention: Baseline FMI
Number of subjects: 785

Group type: EXPERIMENTAL
Intervention: Normal-weight children
Number of subjects: 785
Study: 22804697

Group type: EXPERIMENTAL
Intervention: Background music played while drinking wine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no specific control mentioned)
Number of subjects: 0
Study: 20550616

Group type: EXPERIMENTAL
Intervention: Ipsilateral pulmonary vein antrum isolation (PVAI) with double Lasso technique and left atrial (LA) linear ablation in patients with persistent AF
Number of subjects: 534
Study: 17192912

Group type: EXPERIMENTAL
Intervention: PSA testing
Number of subjects: 2483

Group type: EXPERIMENTAL
Intervention: DRE and TRUS
Number of subjects: 2483

Group type: EXPERIMENTAL
Intervention: Prostate volume
Number of subjects: 2483
Study: 15277966

Group type: EXPERIMENTAL
Intervention: Pumping stroke pattern
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Semicircular stroke pattern
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Timing variables and negative power deflections
Number of subjects: 24
Study: 11241803

Group type: EXPERIMENTAL
Intervention: Indomethacin (i.v. 0.2 mg/kg b.w.)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Isotonic saline (placebo, 20 mL)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Acetylsalicylate (i.v. 500 mg)
Number of subjects: 10
Study: 9647934

Group type: EXPERIMENTAL
Intervention: Testosterone replacement therapy in hypogonadal men
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Testosterone in eugonadal men (male contraceptive clinical trial)
Number of subjects: 62

Group type: COMPARATOR
Intervention: No testosterone administration in eugonadal men
Number of subjects: 62
Study: 8304358

Group type: EXPERIMENTAL
Intervention: Walking more than 7.5 miles per week
Number of subjects: 239

Group type: COMPARATOR
Intervention: Walking less than 1 mile per week
Number of subjects: 239

Group type: EXPERIMENTAL
Intervention: Current level of walking activity
Number of subjects: 239
Study: 2658669

Group type: EXPERIMENTAL
Intervention: 0.8 g/kg ethanol
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo drink
Number of subjects: 44
Study: 31895002

Group type: EXPERIMENTAL
Intervention: Tamsulosin plus mirabegron
Number of subjects: 676

Group type: COMPARATOR
Intervention: Tamsulosin plus placebo
Number of subjects: 676
Study: 31068229

Group type: EXPERIMENTAL
Intervention: Old fashioned oats (OFO)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Steel-cut oats (SCO)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Instant oats (IO)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Cream of Rice (CR)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Honey Nut Cheerios (HNC)
Number of subjects: 30
Study: 28454829

Group type: EXPERIMENTAL
Intervention: FFR-guided complete revascularization
Number of subjects: 885

Group type: COMPARATOR
Intervention: Culprit lesion treatment-only strategy
Number of subjects: 885
Study: 26829596

Group type: EXPERIMENTAL
Intervention: POR*1/*1 genotype
Number of subjects: 229

Group type: EXPERIMENTAL
Intervention: POR*1/*28 genotype
Number of subjects: 229

Group type: EXPERIMENTAL
Intervention: POR*28/*28 genotype
Number of subjects: 229

Group type: COMPARATOR
Intervention: CYP3A5 expressing KTR
Number of subjects: 229
Study: 24267005

Group type: EXPERIMENTAL
Intervention: Fortified milk (100 IU vitamin D, 500 mg calcium per 200 mL)
Number of subjects: 410

Group type: EXPERIMENTAL
Intervention: Fortified orange juice (100 IU vitamin D, 500 mg calcium per 200 mL)
Number of subjects: 410

Group type: EXPERIMENTAL
Intervention: Supplement (200 IU vitamin D, 500 mg calcium)
Number of subjects: 410

Group type: COMPARATOR
Intervention: Plain milk
Number of subjects: 410

Group type: COMPARATOR
Intervention: Fortified milk
Number of subjects: 410

Group type: COMPARATOR
Intervention: Fortified orange juice
Number of subjects: 410
Study: 22587997

Group type: EXPERIMENTAL
Intervention: Corifollitropin alfa
Number of subjects: 677

Group type: COMPARATOR
Intervention: Daily recombinant FSH (rFSH)
Number of subjects: 677

Group type: EXPERIMENTAL
Intervention: Corifollitropin alfa (overall assessment)
Number of subjects: 677
Study: 20546366

Group type: EXPERIMENTAL
Intervention: Protocolized intervention for hospital discharge and follow-up planning
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 0
Study: 17954800

Group type: EXPERIMENTAL
Intervention: Chlorhexidine-based solution (0.25% chlorhexidine gluconate, 0.025% benzalkonium chloride, and 4% benzylic alcohol)
Number of subjects: 538

Group type: COMPARATOR
Intervention: Povidone-iodine (5% povidone-iodine in 70% ethanol)
Number of subjects: 538
Study: 15812409

Group type: EXPERIMENTAL
Intervention: Fibrin glue
Number of subjects: 0

Group type: COMPARATOR
Intervention: Saline solution
Number of subjects: 0
Study: 11956391

Group type: EXPERIMENTAL
Intervention: Surgical stabilization with Judet struts (S group)
Number of subjects: 37
Study: 9793697

Group type: EXPERIMENTAL
Intervention: Migraine and TTH with psychiatric comorbidity (P-Co)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Presence of psychiatric comorbidity (P-Co) in 1988
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Headache-free subjects in 1996
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Anxiety disorders in 1988
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Migraine
Number of subjects: 100
Study: 9613336

Group type: EXPERIMENTAL
Intervention: Shoulder Disability Questionnaire (SDQ)
Number of subjects: 349

Group type: EXPERIMENTAL
Intervention: Pain Severity Scale (PSS)
Number of subjects: 349

Group type: EXPERIMENTAL
Intervention: Functional Status Questionnaire (FSQ)
Number of subjects: 349
Study: 1927943

Group type: EXPERIMENTAL
Intervention: Continuous use of transdermal nitroglycerin (10 mg/24 hours)
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Intermittent use of transdermal nitroglycerin (10 mg/24 hours)
Number of subjects: 127

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: All groups (including placebo)
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: All actively treated patients
Number of subjects: 127
Study: 6356740

Group type: EXPERIMENTAL
Intervention: Gangliosides (20 mg daily i.m.)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 140
Study: 30668157

Group type: EXPERIMENTAL
Intervention: Combined Low‐intensive Psychoeducational Intervention (CLI‐PEI)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Treatment As Usual
Number of subjects: 43
Study: 30593607

Group type: EXPERIMENTAL
Intervention: MEDI4166 50 mg
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: MEDI4166 200 mg
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: MEDI4166 400 mg
Number of subjects: 78

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 78
Study: 28051761

Group type: EXPERIMENTAL
Intervention: Mobile-monitoring intervention
Number of subjects: 42
Study: 26609704

Group type: EXPERIMENTAL
Intervention: SI-DMI (dance/movement intervention focusing on interpersonal movement imitation and synchronization)
Number of subjects: 55

Group type: COMPARATOR
Intervention: CMI (control movement intervention focusing on individual motor coordination)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: SI-DMI
Number of subjects: 55

Group type: COMPARATOR
Intervention: CMI
Number of subjects: 55
Study: 26808856

Group type: EXPERIMENTAL
Intervention: Caffeine (CAF) 6 mg·kg body mass
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Caffeine (CAF)
Number of subjects: 6
Study: 24314193

Group type: EXPERIMENTAL
Intervention: Transient lower esophageal sphincter relaxation (TLESR) mechanism
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Gastroesophageal function evaluation
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Impedance study
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Gastric emptying evaluation
Number of subjects: 20